The primary endpoint of the BETonMACE trial is time to first occurence of strict 3-point major adverse cardiac events (MACE): cardiovascular death, non-fatal myocardial infarction, non-fatal stroke. Those are cardiovascular outcomes. Since the finalization of trial design last year, BETonMACE has always been a cardiovascular outcomes trial (CVOT).